Drug intelligence / Profile preview

Golimumab + Placebo (Clinical Trial Arm)

Development stage: Unknown
Lead developer: Janssen Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

This entry refers to a specific arm within a clinical trial setup, where patients receive golimumab (a fully human IgG1κ monoclonal antibody targeting TNFα) concurrently with a placebo (an inert substance used as a control for another intervention being tested). It is not a fixed-dose combination product available for commercial use. Golimumab is indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and ulcerative colitis.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Golimumab + Placebo (Clinical Trial Arm).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Golimumab + Placebo (Clinical Trial Arm).

Explore the full profile